# ImageneBio, Inc.: financial statements, quarterly

IMA · Nasdaq · CIK 1835579 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ima.md) · [Financials](/companies/ima/financials.md) · [Filings](/companies/ima/filings.md) · [Insiders](/companies/ima/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ima/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.2](/filings/0000950170-24-122818.md) | [0.7 d](/filings/0000950170-25-034188.md) | not reported | not reported | [3.5](/filings/0001193125-25-275932.md) | [0.0 d](/filings/0001193125-26-099434.md) | [0.8](/filings/0001193125-26-212073.md) | [0.0 d](/filings/0001193125-26-333920.md) | [0.0](/filings/0001193125-25-275932.md) | [0.0 d](/filings/0001193125-26-099434.md) | not reported | not reported |
| Research and development | $m | [14.7](/filings/0000950170-24-122818.md) | [14.3 d](/filings/0000950170-25-034188.md) | [9.6](/filings/0000950170-25-066411.md) | [9.8](/filings/0000950170-25-098414.md) | [3.9](/filings/0001193125-25-275932.md) | [3.8 d](/filings/0001193125-26-099434.md) | [4.0](/filings/0001193125-26-212073.md) | [5.7](/filings/0001193125-26-333920.md) | [15.6](/filings/0001193125-25-275932.md) | [3.3 d](/filings/0001193125-26-099434.md) | [6.0](/filings/0001193125-26-212073.md) | [6.7](/filings/0001193125-26-333920.md) |
| Operating income | $m | [(19.5)](/filings/0000950170-24-122818.md) | [(21.9) d](/filings/0000950170-25-034188.md) | [(18.2)](/filings/0000950170-25-066411.md) | [(15.8)](/filings/0000950170-25-098414.md) | [(2.0)](/filings/0001193125-25-275932.md) | [(6.1) d](/filings/0001193125-26-099434.md) | [(6.0)](/filings/0001193125-26-212073.md) | [(7.4)](/filings/0001193125-26-333920.md) | [(26.6)](/filings/0001193125-25-275932.md) | [(8.5) d](/filings/0001193125-26-099434.md) | [(12.1)](/filings/0001193125-26-212073.md) | [(11.8)](/filings/0001193125-26-333920.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0000950170-25-066411.md) | [0.1](/filings/0000950170-25-098414.md) | [0.0](/filings/0001193125-25-275932.md) | [0.0 d](/filings/0001193125-26-099434.md) | [0.0](/filings/0000950170-25-066411.md) | [0.0](/filings/0000950170-25-098414.md) | [(0.1)](/filings/0001193125-25-275932.md) | [(0.3) d](/filings/0001193125-26-099434.md) | [0.0](/filings/0001193125-26-212073.md) | [0.0](/filings/0001193125-26-333920.md) |
| Net income | $m | [(17.3)](/filings/0000950170-24-122818.md) | [(19.5) d](/filings/0000950170-25-034188.md) | [(22.3)](/filings/0001193125-25-275932.md) | [(6.3)](/filings/0001193125-25-275932.md) | [(3.2)](/filings/0001193125-25-275932.md) | [(4.8) d](/filings/0001193125-26-099434.md) | [(6.1)](/filings/0001193125-26-333920.md) | [(7.6)](/filings/0001193125-26-333920.md) | [(24.8)](/filings/0001193125-25-275932.md) | [(6.9) d](/filings/0001193125-26-099434.md) | [(10.6)](/filings/0001193125-26-333920.md) | [(10.2)](/filings/0001193125-26-333920.md) |
| Diluted EPS | $ per share | [(0.40)](/filings/0000950170-24-122818.md) | not reported | [(0.33)](/filings/0000950170-25-066411.md) | [(0.28)](/filings/0000950170-25-098414.md) | [(2.58)](/filings/0001193125-25-275932.md) | not reported | [(3.80)](/filings/0001193125-26-212073.md) | [(4.46)](/filings/0001193125-26-333920.md) | [(2.91)](/filings/0001193125-25-275932.md) | not reported | [(0.95)](/filings/0001193125-26-212073.md) | [(0.63)](/filings/0001193125-26-333920.md) |
| Basic EPS | $ per share | [(0.40)](/filings/0000950170-24-122818.md) | not reported | [(0.33)](/filings/0000950170-25-066411.md) | [(0.28)](/filings/0000950170-25-098414.md) | [(2.58)](/filings/0001193125-25-275932.md) | not reported | [(3.80)](/filings/0001193125-26-212073.md) | [(4.46)](/filings/0001193125-26-333920.md) | [(2.91)](/filings/0001193125-25-275932.md) | not reported | [(0.95)](/filings/0001193125-26-212073.md) | [(0.63)](/filings/0001193125-26-333920.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [121](/filings/0000950170-24-122818.md) | [120](/filings/0000950170-25-034188.md) | [52.9](/filings/0000950170-25-066411.md) | [44.3](/filings/0000950170-25-098414.md) | [45.2](/filings/0000950170-24-122818.md) | [12.1](/filings/0001193125-26-099434.md) | [36.8](/filings/0000950170-25-066411.md) | [58.3](/filings/0000950170-25-098414.md) | [103](/filings/0001193125-25-275932.md) | [94.5](/filings/0001193125-26-333920.md) | [76.0](/filings/0001193125-26-212073.md) | [94.7](/filings/0001193125-26-333920.md) |
| Current assets | $m | [201](/filings/0000950170-23-061535.md) | [179](/filings/0000950170-25-034188.md) | [161](/filings/0000950170-24-058715.md) | [149](/filings/0000950170-24-093880.md) | [142](/filings/0000950170-24-122818.md) | [12.5](/filings/0001193125-26-099434.md) | [117](/filings/0000950170-25-066411.md) | [99.0](/filings/0000950170-25-098414.md) | [148](/filings/0001193125-25-275932.md) | [140](/filings/0001193125-26-333920.md) | [122](/filings/0001193125-26-212073.md) | [141](/filings/0001193125-26-333920.md) |
| Total assets | $m | [215](/filings/0000950170-23-061535.md) | [192](/filings/0000950170-25-034188.md) | [173](/filings/0000950170-24-058715.md) | [157](/filings/0000950170-24-093880.md) | [149](/filings/0000950170-24-122818.md) | [15.9](/filings/0001193125-26-099434.md) | [131](/filings/0000950170-25-066411.md) | [126](/filings/0000950170-25-098414.md) | [161](/filings/0001193125-25-275932.md) | [153](/filings/0001193125-26-333920.md) | [137](/filings/0001193125-26-212073.md) | [152](/filings/0001193125-26-333920.md) |
| Current liabilities | $m | [19.3](/filings/0000950170-23-061535.md) | [14.2](/filings/0000950170-25-034188.md) | [10.2](/filings/0000950170-24-058715.md) | [8.2](/filings/0000950170-24-093880.md) | [9.2](/filings/0000950170-24-122818.md) | [17.2](/filings/0001193125-26-099434.md) | [8.8](/filings/0000950170-25-066411.md) | [7.3](/filings/0000950170-25-098414.md) | [11.1](/filings/0001193125-25-275932.md) | [11.2](/filings/0001193125-26-333920.md) | [6.6](/filings/0001193125-26-212073.md) | [6.6](/filings/0001193125-26-333920.md) |
| Total liabilities | $m | [28.1](/filings/0000950170-23-061535.md) | [22.3](/filings/0000950170-25-034188.md) | [17.4](/filings/0000950170-24-058715.md) | [14.6](/filings/0000950170-24-093880.md) | [14.8](/filings/0000950170-24-122818.md) | [17.4](/filings/0001193125-26-099434.md) | [12.6](/filings/0000950170-25-066411.md) | [10.3](/filings/0000950170-25-098414.md) | [21.0](/filings/0001193125-25-275932.md) | [19.8](/filings/0001193125-26-333920.md) | [13.4](/filings/0001193125-26-212073.md) | [10.0](/filings/0001193125-26-333920.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [7.5](/filings/0001193125-26-099434.md) | not reported | not reported | [0.0](/filings/0001193125-25-275932.md) | [0.0](/filings/0001193125-26-099434.md) | not reported | not reported |
| Shareholders' equity | $m | [155](/filings/0000950170-24-122818.md) | [(126)](/filings/0001193125-26-099434.md) | [(137)](/filings/0001193125-25-275932.md) | [(147)](/filings/0001193125-25-275932.md) | [(153)](/filings/0001193125-25-275932.md) | [(161)](/filings/0001193125-26-333920.md) | [(170)](/filings/0001193125-26-333920.md) | [(180)](/filings/0001193125-26-333920.md) | [140](/filings/0001193125-25-275932.md) | [133](/filings/0001193125-26-333920.md) | [123](/filings/0001193125-26-333920.md) | [142](/filings/0001193125-26-333920.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.0) d](/filings/0000950170-24-122818.md) | [(21.8) d](/filings/0000950170-25-034188.md) | [(18.3)](/filings/0000950170-25-066411.md) | [(12.5) d](/filings/0000950170-25-098414.md) | [13.0 d](/filings/0001193125-25-275932.md) | [(3.5) d](/filings/0001193125-26-099434.md) | [(7.2)](/filings/0001193125-26-212073.md) | [(11.9) d](/filings/0001193125-26-333920.md) | [(21.5) d](/filings/0001193125-25-275932.md) | [(7.2) d](/filings/0001193125-26-099434.md) | [(14.8)](/filings/0001193125-26-212073.md) | [(9.1) d](/filings/0001193125-26-333920.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-122818.md) | [0.3 d](/filings/0000950170-25-034188.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-122818.md) | [0.0 d](/filings/0000950170-25-034188.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.2](/filings/0000950170-23-040943.md) | [36.3](/filings/0000950170-23-061535.md) | [36.3](/filings/0000950170-24-058715.md) | [39.3](/filings/0000950170-24-093880.md) | [43.4](/filings/0000950170-24-122818.md) | [48.3](/filings/0000950170-25-066411.md) | [48.3](/filings/0000950170-25-098414.md) | [48.3](/filings/0000950170-24-122818.md) | [2.4](/filings/0001193125-26-212073.md) | [2.4](/filings/0001193125-26-333920.md) | [11.2](/filings/0001193125-26-212073.md) | [16.2](/filings/0001193125-26-333920.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 11,351,456 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333920.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.